Soligenix, Inc. - SNGX STOCK NEWS

Soligenix (Nasdaq: SNGX) is hosting an exclusive live investor webinar on September 18, 2024, at 4:15 p.m. ET. CEO Christopher J. Schaber will discuss the company's development pipeline and upcoming milestones. Key highlights include:

1. HyBryte™ for cutaneous T-cell lymphoma (CTCL), with positive Phase 3 results and a follow-up study planned.

2. SGX302 for psoriasis, currently in Phase 2a trials.

3. SGX945 for Behçet's Disease, with a Phase 2a study starting this year.

4. ThermoVax® heat stable vaccine platform technology.

The company's pipeline targets a potential $2 billion in annual global sales. Investors can register for the free webinar and submit questions in advance.

Soligenix (NASDAQ: SNGX) has been granted a European patent for its novel method of producing synthetic hypericin, the active ingredient in HyBryte™, a photodynamic therapy for cutaneous T-cell lymphoma (CTCL). This patent (EP3423428) complements a similar US patent and is expected to expire in 2036. HyBryte™ is a first-in-class treatment that uses visible light to activate hypericin applied to CTCL skin lesions, avoiding risks associated with DNA-damaging chemotherapies and UV-dependent therapies.

The company is set to initiate a confirmatory Phase 3 clinical trial (FLASH2) for HyBryte™ in Q4 2024, following statistically significant efficacy results in a previous Phase 3 trial. Soligenix aims to address the unmet medical need in CTCL, an orphan disease, with support from organizations like the Cutaneous Lymphoma Foundation.

RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. on Bloomberg TV on August 17, 2024. Soligenix, a late-stage biopharmaceutical company, highlights its strong portfolio with products targeting a potential $2 billion in annual global sales. Key developments include:

1. HyBryte™, a photodynamic therapy for cutaneous T-cell lymphoma, with positive Phase 3 results and $250 million market potential.

2. SGX302 for psoriasis in Phase 2a trial, with over $1 billion market potential.

3. SGX945 for Behçet's Disease, entering Phase 2a later this year.

4. Collaborations and non-dilutive funding supporting vaccine development, including a filovirus vaccine program showing complete protection in non-human primates.

Soligenix (Nasdaq: SNGX) reported its Q2 2024 financial results and recent accomplishments. Key highlights include:

1. Positive clinical results from a comparability study of HyBryte™ vs. Valchlor® in CTCL treatment, showing a three-fold higher response rate and better safety profile.

2. Upcoming initiation of a confirmatory Phase 3 study for HyBryte™ in early-stage CTCL.

3. Planned Phase 2 study of SGX945 in Behçet's disease, with top-line results expected in H1 2025.

4. Q2 2024 financial results: revenues of <$0.1M, net loss of $1.6M ($1.31 per share), and cash position of $9.1M as of June 30, 2024.

5. Regained compliance with Nasdaq's Minimum Bid Price Rule.

Soligenix, a late-stage biopharmaceutical company, announced promising interim results for its HyBryte™ treatment in an open-label, investigator-initiated study for early-stage cutaneous T-cell lymphoma (CTCL). Supported by a $2.6 million FDA Orphan Products Development Grant, the study evaluated HyBryte™ treatment extended up to 12 months. Six patients have been enrolled, with 75% of patients who completed at least 12 weeks of therapy achieving 'Treatment Success,' defined as a ≥50% improvement in their cumulative mCAILS score. The treatment has been well-tolerated with no adverse events reported. The study aims to enroll up to 50 patients and will provide additional data as it progresses.

Soligenix announced positive results from a comparative study evaluating HyBryte™ against Valchlor® for treating cutaneous T-cell lymphoma (CTCL). The open-label study involved 10 patients over a 12-week treatment period. Results showed that 60% of HyBryte™ patients achieved a 50% or greater improvement in their mCAILS score, compared to 20% for Valchlor®. HyBryte™ also demonstrated a more favorable safety profile, with no adverse events reported, while 60% of Valchlor® patients experienced therapy-related adverse events. The study supports previous Phase 2 and 3 findings and sets the stage for a Phase 3 placebo-controlled study later this year.

Soligenix, a biopharmaceutical firm, announced that Professor Axel Lehrer will present key data on the company's thermostable vaccine platform at the ASM Microbe Conference, June 13-17, 2024. The discussion will include results from the filovirus vaccine candidates SuVax™ and MarVax™ for Sudan ebolavirus and Marburg marburgvirus. These vaccines, developed with the University of Hawaiʽi, use a thermostabilization method that enables stability at higher temperatures, simplifying logistics. The vaccines have shown complete protection in non-human primate studies. Soligenix has also received Orphan Drug Designation for these vaccines.

Soligenix and Sharps Technology will be featured in interviews on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing June 8 at 7 p.m. ET. Soligenix, a late-stage biopharmaceutical company, highlights its promising portfolio, including HyBryte™ for cutaneous T-cell lymphoma, which showed positive Phase 3 results and has a $250 million market potential. It also features SGX302 for psoriasis and SGX203 for pediatric Crohn's disease, targeting markets over $1 billion collectively. Sharps Technology, meanwhile, has secured a $200 million Sales Agreement and acquired Nephron Pharmaceuticals' InjectEZ facility, positioning itself as North America's first dedicated polymer prefillable syringe manufacturer. Projected revenues include $35 million in the first 12 months, with potential growth up to $100 million by 2028.

Soligenix (NASDAQ: SNGX) announced a reverse stock split at a 1-for-16 ratio, effective at 4:00 p.m. on June 5, 2024. Trading on a split-adjusted basis will begin June 6, 2024. The reverse split will reduce the number of outstanding shares from approximately 15.8 million to around 987,490 shares. Stockholders' equity percentage remains unchanged, and fractional shares will be rounded up. No new stock certificates are required, but proportional adjustments will be made to equity awards and warrants. Stockholders with brokerage accounts will see automatic adjustments. The new CUSIP number is 834224 604.